Drug Trial Radar · NCT05027139
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Sep 15, 2021
Primary completion
Aug 29, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- ALX Oncology Inc.
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Conditions
- HER2-expressing Cancers
Interventions
ZanidatamabDrug
Administered intravenously (IV)
EvorpaceptDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs; Part 1)Time frame: Up to 4 weeks
- Incidence of AEs (Part 1)Time frame: Up to 7 months
- Incidence of clinical laboratory abnormalities (Part 1)Time frame: Up to 7 months
- Confirmed objective response rate (ORR)(Part 2)Time frame: Up to 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
UC San Diego - Moores Cancer Center
La Jolla, California
UCLA Department of Medicine Hematology/Oncology
Los Angeles, California
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California
Florida Cancer Specialists
Sarasota, Florida
Astera Cancer Care
East Brunswick, New Jersey
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
Northwest Medical Specialties, PLLC
Tacoma, Washington
University of Wisconsin - Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.